XSAT:HAMLET B (Sweden)
Business Description
Hamlet Pharma AB
Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Compare
Compare
Traded in other countries / regions
7ZT.Germany
•
HAMLET B.Sweden
•
HMPMF.USA
Description
Hamlet Pharma AB is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.95 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 24.4 | |||||
| 3-Year EPS without NRI Growth Rate | 23.9 | |||||
| 3-Year FCF Growth Rate | 32 | |||||
| 3-Year Book Growth Rate | -44.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.54 | |||||
| 9-Day RSI | 49.39 | |||||
| 14-Day RSI | 50.4 | |||||
| 6-1 Month Momentum % | -29.23 | |||||
| 12-1 Month Momentum % | -42.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.43 | |||||
| Quick Ratio | 18.43 | |||||
| Cash Ratio | 17.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -36.19 | |||||
| ROA % | -29.97 | |||||
| ROIC % | -206.98 | |||||
| ROC (Joel Greenblatt) % | -54172.22 | |||||
| ROCE % | -35.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.93 | |||||
| Price-to-Tangible-Book | 10.95 | |||||
| EV-to-EBIT | -41.74 | |||||
| EV-to-EBITDA | -41.82 | |||||
| EV-to-FCF | -32.36 | |||||
| Price-to-Net-Current-Asset-Value | 10.95 | |||||
| Price-to-Net-Cash | 11.57 | |||||
| Earnings Yield (Greenblatt) % | -2.39 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0 | ||
| EPS (TTM) (kr) | -0.093 | ||
| Beta | 0 | ||
| Volatility % | 36.01 | ||
| 14-Day RSI | 50.4 | ||
| 14-Day ATR (kr) | 0.320852 | ||
| 20-Day SMA (kr) | 4.0915 | ||
| 12-1 Month Momentum % | -42.71 | ||
| 52-Week Range (kr) | 3.005 - 7.97 | ||
| Shares Outstanding (Mil) | 110.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hamlet Pharma AB Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||